AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-08-18
Target enrollment:
Participant gender:
Summary
This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the
safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung
cance. This study is divided into 3 periods: dose escalation stage, dose extension stage, and
efficacy extension stage.